secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001551152-25-000002
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie reports $1.574B Q4 IPR&D charge, cuts adjusted EPS guidance by $0.88
---------------------------------------------------------------------------

- Expected Q4 2024 acquired IPR&D and milestones expense of $1,574M pre-tax, $0.88 per share impact.
- Adjusted diluted EPS guidance for Q4 2024 revised to $2.06-$2.10 (from $2.94-$2.98).
- Full-year 2024 adjusted diluted EPS guidance revised to $10.02-$10.06 (from $10.90-$10.94).
- Previous guidance excluded Q4 IPR&D expense; company does not forecast such expenses.
- Q4 2024 results not finalized; subject to closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000002/0001551152-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000002/abbv-20250106.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer